Jane Street Group LLC Has $167,000 Position in ChromaDex Co. (NASDAQ:CDXC)

Jane Street Group LLC raised its stake in shares of ChromaDex Co. (NASDAQ:CDXC) by 100.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 45,712 shares of the company’s stock after purchasing an additional 22,889 shares during the quarter. Jane Street Group LLC owned 0.06% of ChromaDex worth $167,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. WINTON GROUP Ltd bought a new position in ChromaDex during the second quarter worth about $597,000. Bank of New York Mellon Corp raised its holdings in shares of ChromaDex by 170.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock worth $520,000 after buying an additional 119,915 shares in the last quarter. BSW Wealth Partners bought a new position in shares of ChromaDex during the 3rd quarter worth approximately $324,000. BNP Paribas Financial Markets boosted its stake in ChromaDex by 1,885.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after buying an additional 69,582 shares in the last quarter. Finally, State Street Corp grew its position in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after acquiring an additional 62,692 shares during the period. Institutional investors and hedge funds own 15.41% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on CDXC shares. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, Roth Mkm raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Insider Activity at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 9.64% of the company’s stock.

ChromaDex Stock Performance

Shares of CDXC stock opened at $5.26 on Tuesday. ChromaDex Co. has a 52 week low of $1.36 and a 52 week high of $7.97. The stock has a market capitalization of $401.77 million, a PE ratio of 526.53 and a beta of 2.21. The stock’s fifty day moving average is $6.41 and its 200-day moving average is $4.38.

ChromaDex (NASDAQ:CDXC) last released its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same period in the prior year, the company posted ($0.01) EPS. As a group, analysts forecast that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.